Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside

Experimental Hematology

Volumn 36, Issue 3, 2008, Pages 319-328

  Lin, Jian Min ^a   Li, Betty ^a   Rimmer, Eric ^a   VanRoey, Melinda ^a   Jooss, Karin ^a  

^a CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; CYTOPENIA; CYTOTOXICITY; DRUG EFFICACY; EUTHANASIA; FEMALE; FLOW CYTOMETRY; IMAGING SYSTEM; IMMUNOTHERAPY; MEMORY; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; LEUKEMIA, MYELOID, ACUTE; LUCIFERASES; LYMPHOPENIA; MICE; MICE, CONGENIC; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PHENOTYPE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 38949151228     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.11.005     Document Type: Article

References (38)

1. Jabbour E.J., Estey E., and Kantarjian H.M. Adult acute myeloid leukemia. Mayo Clin Proc 81 (2006) 247-260
2. Kayaga J., Souberbielle B.E., Sheikh N., et al. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 6 (1999) 1475-1481
3. Abou-Jawde R.M., Sobecks R., Pohlman B., et al. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 47 (2006) 689-695
4. Stone R.M. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 39 Suppl 2 (2002) 4-10
5. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332 (1995) 1671-1677
6. Lowenberg B., Boogaerts M.A., Daenen S.M., et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15 (1997) 3496-3506
7. Simmons AD, Li B, Gonzalez-Edick M, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 56:1653-1665.
8. Weber J., Sondak V.K., Scotland R., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97 (2003) 186-200
9. Barrio M.M., de Motta P.T., Kaplan J., et al. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother. (1997) 29 (2006) 444-454
10. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
11. von Mehren M., Arlen P., Gulley J., et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7 (2001) 1181-1191
12. Dunussi-Joannopoulos K., Dranoff G., Weinstein H.J., Ferrara J.L., Bierer B.E., and Croop J.M. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 91 (1998) 222-230
13. Mach N., and Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12 (2000) 571-575
14. Hu H.M., Winter H., Urba W.J., and Fox B.A. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 165 (2000) 4246-4253
15. Soiffer R., Hodi F.S., Haluska F., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21 (2003) 3343-3350
16. Herrlinger U., Kramm C.M., Johnston K.M., et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4 (1997) 345-352
17. Simons J.W., Mikhak B., Chang J.F., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 (1999) 5160-5168
18. Jaffee E.M., Hruban R.H., Biedrzycki B., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19 (2001) 145-156
19. Dranoff G., Soiffer R., Lynch T., et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 8 (1997) 111-123
20. Lim M., and Simons J.W. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Curr Opin Mol Ther 1 (1999) 64-71
21. Chu Y., Wang L.X., Yang G., et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29 (2006) 367-380
22. Kusumoto M., Umeda S., Ikubo A., et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50 (2001) 373-381
23. Prell R.A., Gearin L., Simmons A., Vanroey M., and Jooss K. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 55 (2006) 1285-1293
24. Nigam A., Yacavone R.F., Zahurak M.L., et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 12 (1998) 161-170
25. Shi F.S., Weber S., Gan J., Rakhmilevich A.L., and Mahvi D.M. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther 6 (1999) 81-88
26. Golumbek P.T., Azhari R., Jaffee E.M., et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53 (1993) 5841-5844
27. Ward S., Casey D., Labarthe M.C., et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51 (2002) 351-357
28. de Vries J.F., Falkenburg J.H., Willemze R., and Barge R.M. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 91 (2006) 912-919
29. Witz F., Sadoun A., Perrin M.C., et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91 (1998) 2722-2730
30. Arellano M.L., Langston A., Winton E., Flowers C.R., and Waller E.K. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 13 (2007) 116-123
31. Schmid C., Schleuning M., Aschan J., et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 18 (2004) 1430-1433
32. Nemunaitis J., Sterman D., Jablons D., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 326-331
33. Ray M.R., Lakshmi C., Deb C., and Pal B. Dopamine accelerates recovery from cyclophosphamide-induced leukopenia. Exp Oncol 22 (2000) 153-156
34. Zhou B., Kong X., and Linzer D.I. Enhanced recovery from thrombocytopenia and neutropenia in mice constitutively expressing a placental hematopoietic cytokine. Endocrinology 146 (2005) 64-70
35. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
36. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202 (2005) 907-912
37. Beyer M., Kochanek M., Darabi K., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
38. Borrello I, Levitsky H, Damon L, et al. Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF-secreting leukemia vaccine and autologous stem cell transplant (ASCT). ASCO 2005. Abstract.